Obsidian Therapeutics (OBX) analyst forecast and price target
Analyst forecast
Consensus of 3 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| LifeSci Capital | Initiated Coverage | Outperform | $43.00 | Aug 18, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $42.00 | Aug 5, 2026 |
Frequently asked questions
Is OBX a buy, sell, or hold?
Analysts covering Obsidian Therapeutics currently average a Buy rating: 3 buy, 0 hold and 0 sell, from 3 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on OBX?
On Aug 18, 2026, LifeSci Capital initiated coverage of Obsidian Therapeutics at Outperform with a price target of $43.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.